Giant-cell tumors of bone: an analysis of 87 cases

Abstract

We reviewed 87 patients with giant-cell tumor treated between 1992 and 2001. The mean follow-up was 62 (28-138) months. Fifty-six lesions were treated with intralesional curettage with adjunctive phenol treatment and reconstructed with autograft and allograft. Thirty-one lesions were treated with wide resection and reconstructed with prosthesis, osteochondral allograft, or alloprosthetic composite. Overall recurrence was 12%. Recurrence rate after curettage was 18% and 3% after wide excision. Complication rate after wide excision was higher than that after curettage. Functional outcome was evaluated using the Enneking scoring system. Average rating was 86% for the lower extremity and 83% for the upper extremity. The overall satisfactory rate was 88%.

Giant Cell Tumor of Bone: Risk Factors for Recurrence

“…Similar to previous reports [1,3,6,15,22,31,45,46], we found wide resection was associated with a lower risk of recurrence than intralesional surgery. When intralesional procedures are performed, local adjuvants (polymethylmethacrylate, phenol, hydrogen peroxide, and cryotherapy) have been reported to improve tumor control [1,3,5,11,28].…”

Which Treatment is the Best for Giant Cell Tumors of the Distal Radius? A Meta-analysis

“…Extension of curettage has been achieved using a highspeed burr combined with adjuvant to preserve joint function, and this method has been associated with a low rate of recurrence (4%-14%) [5,6,12,13,23,25,27,36,44,48,52,53,56]. Therefore, our objective was to identify cases of GCTs of the distal radius to determine whether curettage is associated with lower rates of recurrences and fewer major complications compared with en bloc excision, and whether recurrence rates differed with the use of PMMA versus bone graft in patients treated with curettage.…”

Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical Management

“…It is the least invasive surgical option and usually provides the possibility to save the joint adjacent to the tumor. Intralesional curettage may be combined with the use of local adjuncts, such as PMMA void filling [1,3,4,15,20,33,37,42,45], hydrogen peroxide [3,4], phenol [15,37,39,40,42], and cryotherapy [24,26,27] with the intention to further reduce the risk of local recurrence.…”